Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Watch out, Gilead and Novartis: there's a new CAR-T in town ... with 3% grade 3 events and no grade 4 or 5 events. Like other CAR-T products, Aucatzyl still comes with an FDA boxed warning for CRS, ...

For pharma companies, the goldilocks earnings scenario is a strong quarterly beat paired with a promising pipeline of innovative drugs. This balance is crucial for the industry, where firms face the ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

TD Cowen analyst Steve Scala maintained a Hold rating on Novartis (NVS – Research Report) today. The company’s shares closed ...

When I (Kody) last covered Novartis with a buy rating in May, I liked its continuity as a business. The company's product portfolio and pipeline were also impressive. Novartis' balance sheet was ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

One of the largest pharmaceutical companies in the world, Novartis AG, has posted strong quarterly results. It comes on the ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...